-+ 0.00%
-+ 0.00%
-+ 0.00%

Aytu BioPharma swings to Q1 FY27 net loss of $3.88 million year over year

PUBT·11/16/2026 21:22:09
Listen to the news
Aytu BioPharma swings to Q1 FY27 net loss of $3.88 million year over year
  • Aytu BioPharma swung to a $3.88 million net loss in Q1 FY27 from $1.97 million net income a year earlier.
  • Net revenue rose 7% year over year to $14.84 million.
  • EXXUA net revenue climbed 25% from Q4 FY26 to $4.9 million, while quarterly prescriptions increased 33% sequentially to 4,400.
  • Rosemont agreed to acquire Aytu for $2.70 per share in cash, valuing the transaction at approximately $56 million fully diluted.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.